Serina Therapeutics Inc
SER2.650USD
-0.007-0.26%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
27.94MMarket Cap
LossP/E TTM
More Details of Serina Therapeutics Inc Company
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics Inc Info
Ticker SymbolSER
Company nameSerina Therapeutics Inc
IPO dateNov 29, 2018
CEOLedger (Steven)
Number of employees12
Security typeOrdinary Share
Fiscal year-endNov 29
Address601 Genome Way,
CityHUNTSVILLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code35806
Phone12563279630
Websitehttps://serinatherapeutics.com/
Ticker SymbolSER
IPO dateNov 29, 2018
CEOLedger (Steven)
Company Executives of Serina Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
130.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
Other
51.65%
Shareholders
Shareholders
Proportion
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
Other
51.65%
Shareholder Types
Shareholders
Proportion
Corporation
39.12%
Individual Investor
8.18%
Investment Advisor
3.01%
Hedge Fund
0.78%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.02%
Other
48.35%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
56
464.13K
4.40%
+21.47K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Juvenescence Ltd
3.27M
31%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
8.59%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
6.72%
-133.79K
-15.88%
Sep 17, 2025
The Vanguard Group, Inc.
150.62K
1.43%
+85.29K
+130.55%
Jun 30, 2025
Ledger (Steven A)
95.73K
0.91%
-227.93K
-70.42%
Sep 17, 2025
Broadwood Capital, Inc.
85.22K
0.81%
--
--
Jun 30, 2025
Waverly Advisors, LLC
67.49K
0.64%
--
--
Jun 30, 2025
Bailey (Gregory Hugh)
67.24K
0.64%
--
--
Sep 17, 2025
Geode Capital Management, L.L.C.
28.88K
0.27%
-322.00
-1.10%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Date
Type
Ratio
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
FAQs
Who are the top five shareholders of Serina Therapeutics Inc?
The top five shareholders of Serina Therapeutics Inc are:
Juvenescence Ltd holds 3.27M shares, accounting for 31.00% of the total shares.
Puffinus L.P. holds 904.88K shares, accounting for 8.59% of the total shares.
McMillan (Helen w) holds 708.61K shares, accounting for 6.72% of the total shares.
The Vanguard Group, Inc. holds 150.62K shares, accounting for 1.43% of the total shares.
Ledger (Steven A) holds 95.73K shares, accounting for 0.91% of the total shares.
Juvenescence Ltd holds 3.27M shares, accounting for 31.00% of the total shares.
Puffinus L.P. holds 904.88K shares, accounting for 8.59% of the total shares.
McMillan (Helen w) holds 708.61K shares, accounting for 6.72% of the total shares.
The Vanguard Group, Inc. holds 150.62K shares, accounting for 1.43% of the total shares.
Ledger (Steven A) holds 95.73K shares, accounting for 0.91% of the total shares.
What are the top three shareholder types of Serina Therapeutics Inc?
The top three shareholder types of Serina Therapeutics Inc are:
Juvenescence Ltd
Puffinus L.P.
McMillan (Helen w)
Juvenescence Ltd
Puffinus L.P.
McMillan (Helen w)
How many institutions hold shares of Serina Therapeutics Inc (SER)?
As of 2025Q3, 56 institutions hold shares of Serina Therapeutics Inc, with a combined market value of approximately 464.13K, accounting for 4.40% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -62.84%.
What is the biggest source of revenue for Serina Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Serina Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
